<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127137</url>
  </required_header>
  <id_info>
    <org_study_id>STU00204980</org_study_id>
    <nct_id>NCT03127137</nct_id>
  </id_info>
  <brief_title>Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized Controlled Trial</brief_title>
  <official_title>Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical radicular pain is relatively common, often treated with epidural steroid injection&#xD;
      (ESI), when conservative treatments like oral analgesics, physical therapy and activity&#xD;
      modification have failed. There are no universal clinical practice guidelines for the use of&#xD;
      diluents when CESI are performed.&#xD;
&#xD;
      Interlaminar CESI may be performed with or without the use of local anesthetics, due to&#xD;
      training bias or theoretical concerns of weakness. CESI without the benefit of local&#xD;
      anesthetic as a steroid diluent increases the latency of pain relief and may decrease&#xD;
      diagnostic information immediately after a CESI with regard to pain generators responsible&#xD;
      for symptoms, and may potentially decrease patient satisfaction.&#xD;
&#xD;
      By evaluating the effects of local anesthetic as a diluent during interlaminar cervical ESI,&#xD;
      we will enhance the safety of this treatment with regard to expectations of objective motor&#xD;
      weakness as well as post procedure pain control and patient satisfaction in the recovery&#xD;
      phase after the injection procedure.&#xD;
&#xD;
      Research Question:&#xD;
&#xD;
      Does lidocaine versus saline as a steroid diluent effect objective upper extremity strength&#xD;
      following cervical epidural steroid injection in patients being treated for cervical&#xD;
      radiculitis?&#xD;
&#xD;
      Null Hypothesis:&#xD;
&#xD;
      Cervical epidural steroid injections that include local anesthetic as a diluent have no&#xD;
      effect on objective upper extremity strength following the injection.&#xD;
&#xD;
      We hypothesized that cervical epidural lidocaine will cause an objective decrease in strength&#xD;
      in functional movements of the upper extremity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control Group: Prospective observational cohort study of UE strength in pain clinic patients&#xD;
      undergoing trigger point injections and occipital nerve injections to serve as controls to&#xD;
      measure variability of strength testing before and 30 min after such an intervention.&#xD;
&#xD;
      Experimental Groups: Prospective, randomized, controlled, double blinded trial in patients&#xD;
      undergoing CESI for symptoms of cervical radiculitis.&#xD;
&#xD;
      Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1%&#xD;
      lidocaine (total volume 4 cc).&#xD;
&#xD;
      Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL&#xD;
      preservative saline (total volume 4 cc).&#xD;
&#xD;
      Adults who are eligible to have a CESI with triamcinolone for treatment of cervical&#xD;
      radiculitis at the Northwestern Anesthesiology Pain Medicine Center will be approached by&#xD;
      authorized research personnel prior to a patient's CESI is performed and will obtain informed&#xD;
      consent from patients who agree to participate.&#xD;
&#xD;
      In every subject (Control Cohort, Group 1 and Group 2) a pre-procedure NRS pain score, and&#xD;
      presence of subjective or objective symptoms of UE weakness will be recorded. Bilateral&#xD;
      handgrip, wrist extension, elbow flexion, and elbow extension strength (myotomes C5-T1) will&#xD;
      be measured by a trained research assistant prior to the injection procedure using a handheld&#xD;
      JAMARÂ® PLUS+ digital dynamometer (Sammons Preston, Bollingbrook, IL) for hand grip strength&#xD;
      and a push/pull handheld hydraulic dynamometer (Balego and Associates Inc., St. Paul, MN) for&#xD;
      arm strength assessment. Three baseline strength measurements will be recorded for each&#xD;
      strength test. Measurements will be taken prior to and 30 minutes following the injection&#xD;
      procedure. Patients in Group #1 and Group #2 will also be queried with the Upper Extremity&#xD;
      Functional Index (UEFI) before the injection procedure and again 1 day after the procedure&#xD;
      (administered via telephone).&#xD;
&#xD;
      For Group 1 and Group 2, patients will be randomized to treatment group based on a random&#xD;
      computer-generated schedule. Participants will be blinded to the group to which they are&#xD;
      randomized. All standard procedures for CESIs will be followed as is standard practice&#xD;
      including time out, skin prep, hemodynamic monitoring, image guidance etc.&#xD;
&#xD;
      Per randomization, triamcinolone acetonide 80 mg (Kenalog) (E. R. Squibb &amp; Sons Limited,&#xD;
      Uxbridge UK) will be combined with 2mL Lidocaine 1% or 2 mL preservative free saline and will&#xD;
      be injected during the CESI procedure. In all cases, the total injectate volume will be 4 mL&#xD;
      in all cases. All injections will be image guided with fluoroscopy, as is the current&#xD;
      standard practice. Fluoroscopy time will be recorded.&#xD;
&#xD;
      The participant will be discharged from the clinic with written discharge instructions&#xD;
      (current standard practice).&#xD;
&#xD;
      Participants will be telephoned by clinic personnel 1 day after the CESI to assess for&#xD;
      subjective weakness in the hands or arms as well as any other adverse reactions. As above,&#xD;
      the Upper Extremity Functional Index will be administered at this time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Controlled Trial using control arm plus 2 arm experimental (placebo and active drug)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participant will be blinded to group assignment. Outcome assessor will also be blinded to the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in strength for each individual in each treatment group before and 30 minutes after CESI</measure>
    <time_frame>Baseline and 30 minutes after the CESI procedure</time_frame>
    <description>Change in strength for each individual in each treatment group before and 30 minutes after CESI using hand held Dynamometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean arterial pressure</measure>
    <time_frame>Baselind and 30 minutes after CESI procedure</time_frame>
    <description>Change in mean arterial pressure prior to and 30 minutes after CESI, via automated blood pressure cuff measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Baseline and 30 minutes after CESI</time_frame>
    <description>Change in heart rate prior to and 30 minutes after CESI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>Baseline and 30 minutes after CESI</time_frame>
    <description>Change in average pain score before and after CESI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UEFI score change</measure>
    <time_frame>Baseline and 30 minutes after CESI</time_frame>
    <description>Change is UEFI (Upper Extremity Functional Index) scores before and after CESI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>Baseline and 24 hours after CESI procedure</time_frame>
    <description>Procedure complications or adverse reactions to medications used</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cervical Radiculitis</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Control cohort Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control cohort group will receive medications not predetermined by the set protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control cohort group</intervention_name>
    <description>Control cohort group will receive medications not predetermined by the set protocol.</description>
    <arm_group_label>Control cohort Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Group 1 triamcinolone and lidocaine</intervention_name>
    <description>Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)</description>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <other_name>Experimental Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Group 2 triamcinolone and saline</intervention_name>
    <description>Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)</description>
    <arm_group_label>Experimental Group 2</arm_group_label>
    <other_name>Experimental Group 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients ages 18 years or older who will undergo CESI for treatment of cervical&#xD;
             radiculitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Lack of consent&#xD;
&#xD;
          -  Any contraindication to CESI&#xD;
&#xD;
          -  Inability to communicate with staff or to participate in follow up&#xD;
&#xD;
          -  Inability to perform handgrip or arm strength testing&#xD;
&#xD;
          -  Cervical spinal cord lesions&#xD;
&#xD;
          -  Cerebrovascular, demyelinating or other neuromuscular muscular disease&#xD;
&#xD;
          -  Patient request for or requirement of conscious sedation for the injection procedure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Sensitivity to amides&#xD;
&#xD;
          -  History of allergy to local anesthetics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Walega, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Walega, M.D.</last_name>
    <phone>312-695-4052</phone>
    <email>d-walega@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walega, M.D.</last_name>
      <phone>312-695-4052</phone>
      <email>d-walega@northwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S; Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000319. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD000319.</citation>
    <PMID>17636629</PMID>
  </reference>
  <reference>
    <citation>Stav A, Ovadia L, Sternberg A, Kaadan M, Weksler N. Cervical epidural steroid injection for cervicobrachialgia. Acta Anaesthesiol Scand. 1993 Aug;37(6):562-6.</citation>
    <PMID>8213020</PMID>
  </reference>
  <reference>
    <citation>Cicala RS, Thoni K, Angel JJ. Long-term results of cervical epidural steroid injections. Clin J Pain. 1989 Jun;5(2):143-5.</citation>
    <PMID>2520395</PMID>
  </reference>
  <reference>
    <citation>Botwin KP, Castellanos R, Rao S, Hanna AF, Torres-Ramos FM, Gruber RD, Bouchlas CG, Fuoco GS. Complications of fluoroscopically guided interlaminar cervical epidural injections. Arch Phys Med Rehabil. 2003 May;84(5):627-33.</citation>
    <PMID>12736872</PMID>
  </reference>
  <reference>
    <citation>Rowlingson JC, Kirschenbaum LP. Epidural analgesic techniques in the management of cervical pain. Anesth Analg. 1986 Sep;65(9):938-42.</citation>
    <PMID>3017152</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>June 1, 2019</last_update_submitted>
  <last_update_submitted_qc>June 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>David Walega</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 6, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

